Inhaled loxapine for agitation in patients with personality disorder: an initial approach
| Autor: | Barbara Patrizi, Miquel Gasol, María V Navarro-Haro |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Time Factors Adolescent Databases Factual media_common.quotation_subject Loxapine Personality Disorders 03 medical and health sciences Young Adult 0302 clinical medicine Psychiatric emergencies Administration Inhalation medicine Personality Humans Pharmacology (medical) In patient Biological Psychiatry Psychomotor Agitation media_common Retrospective Studies Pharmacology business.industry Middle Aged 030227 psychiatry Psychiatry and Mental health Treatment Outcome Neurology Anesthesia Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Zdroj: | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 29(1) |
| ISSN: | 1873-7862 |
| Popis: | Inhaled Loxapine (IL) has demonstrated efficacy in the treatment of agitation in schizophrenic and bipolar patients, although data in patients with Personality Disorder (PD) are scarce. To evaluate the effectiveness and safety of IL in the treatment of agitation in PD, data from 41 patients who presented at our unit with acute agitation and were treated with 9.1 mg of IL were collected retrospectively. The results showed that IL significantly decreased agitation within 10 minutes and its effect was greater at 20 minutes (Positive and Negative Syndrome Scale-excited component: from 22.78 ± 4.39 at baseline to 11.14 ± 4.17 at 20 minutes; p 0.001; Agitation and Calmness Evaluation Scale: from 1.80 ± 0.49 at baseline to 4.53 ± 1.05 at 20 minutes; p 0.01) without any severe adverse reactions registered. IL led to fast, safe and well-tolerated control of agitation in patients with PD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect